NeuroOne is a medical technology company focused on revolutionizing the standard of care for patients suffering from conditions such as epilepsy, Parkinson’s disease, dystonia, essential tremors, and other related brain disorders. We believe our thin film electrodes will be able to be placed with minimally invasive procedures and improve the outcomes for patients with neurological disorders. Additionally, we believe that the higher resolution provided by our electrodes can enable the usage of powerful computing techniques such as machine learning and artificial intelligence.
2017 was a transformational year for us. We completed a reverse merger, up-listed to the OTCQB and raised over $1.8 million in private transactions. Strategically, we established a physician advisory board, completed an early feasibility study for our depth electrode and combination diagnostic/ablation depth electrode1, and filed two provisional patents with the USPTO.
In 2018, we recruited thought leaders and highly renowned AI neurosurgeons to establish our Artificial Intelligence Advisory board. We also established our headquarters, conducted multiple rounds of pre-clinical testing on our ablation electrode2 and a pre-clinical feasibility study for minimally invasive placement of our cortical electrodes at Mayo Clinic3.
For 2019, we expect to debut our cortical electrodes, pending FDA 510(k) clearance. We submitted a 510(k) filing to the FDA for our cortical electrode product line and plan to submit our depth electrode product line later this year. Upon clearance, we intend to launch our electrode products to targeted industry leading, medical centers. We also plan on exploring additional product applications with insight from our AI advisory board.
NeuroOne entered into a license and development agreement with Mayo Clinic. NeuroOne licensed worldwide certain know how for the development and commercialization of products, methods and processes related to flexible circuit thin film technology for the recording of tissue and the products developed therefrom.
Wisconsin Alumni Research Foundation
NeuroOne entered into an Exclusive Start-Up Company License Agreement with the Wisconsin Alumni Research Foundation (WARF). WARF granted NeuroOne an exclusive license to make, use and sell, in the U.S. products that employ certain licensed patents for a neural probe array or thin-film micro electrode array and method.
NeuroOne is developing minimally invasive solutions for brain related disorders which include epilepsy, essential tremors, Parkinson’s disease, dystonia and other neurological conditions. We are focused on the development and commercialization of thin film electrodes for use in Intracranial (iEEG) recording and stimulation for Electrocorticography (ECoG), Stereoelectroencephalography (sEEG), ablation as well as electrodes capable of providing chronic stimulation.
Our electrodes have a new thin film technology which may reduce patient complications during procedures, allow for minimally invasive placement, are designed to provide better signal clarity in recording brain activity for diagnosis, and may reduce the cost of care while improving patient outcomes.
Why NeuroOne’s Electrode Solution is Better
In comparison to currently available technologies, we are developing thin film electrodes with the goal of reducing overall procedure times, reducing the invasiveness and risks of the procedure, improving the comfort of the patient, and improving the accuracy of diagnosis so patients suffering from neurological disorders may have a better quality of life.